{"name":"Palatin Technologies, Inc","slug":"palatin-technologies-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":14898494,"netIncome":-17307349,"cash":3266954,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RAAS inhibition therapy","genericName":"RAAS inhibition therapy","slug":"raas-inhibition-therapy","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"RAAS inhibition therapy","genericName":"RAAS inhibition therapy","slug":"raas-inhibition-therapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOREVaTzJ5bW5WVTNJb3RyT3RRdks2bW8wOHZialZhTWU5d1NueG4yQ0o1czhLTkZmMF9OcFQwWW5iZVdtOU56X29scDFPamgxSGxiZklFVXFyb0tQMXJCeXY3VHBzeG9YeFV3NzZJWGJrRWcwcDR5eHJITTJqdFhlak5FY3dwMkZUMUxzQW9jNmFNN1M4VkdTTEh5LS1zSTVvWkRrQ0JOekdpZGREVlUtZmZFZVBhSkYtNUZSUE5waW9HenROZ294WU52XzN5SDZZY1JxRDA4RlM1ZFBIejAzNWFiOUtaeG1uTTE0VHFGWkpCbS1abEZz?oc=5","date":"2026-02-18","type":"pipeline","source":"TradingView","summary":"Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN) - TradingView","headline":"Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline (NYSE: PTN)","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOUklZNURWMTFWdmEwdU5CbVM0NXhKQWZoV0xQMVduM3dRZ09LeWg5T2VDTFIxRDRCd1FqNnk5XzAyTHpKUFN0cGJsSGkxamNzSGZUOTVWTVdKM0pTUXFSVGltbHA3QktHSXpBX0h1dnJEZVEzODBuaFdqbWYzRkJiVUNVQWVETFA2dHBnVTA2dGRzMmd6TDN1QnFCTzBIWWNiaDNDckdUTFItS1dFaUI2S01SY2s3TWRTWU43T3NwUjJoUW1WSzdnQzE0R1k?oc=5","date":"2025-12-12","type":"deal","source":"Investing.com","summary":"Laidlaw initiates coverage on Palatin Technologies stock with Buy rating - Investing.com","headline":"Laidlaw initiates coverage on Palatin Technologies stock with Buy rating","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxQVnkxcjg4RG9icWhEU3llcUhuLUhkQVJreFhQZWRJdW5nLXl4UHNqVEhNZ0xEUFJWSlhCZnhvMDlncElkTUNQNmZzZ2NMVWRtYmVjb19yV1VPN0Vid3ZEdGlKUU1mdTMwZVByNWZVVzZETG9hQ3NRdjNmWm5BbWFnSFB1SkhDeGVMSk13ZFozUjBvek9GZ1c5LThseEVpc2VvWjFPU00zbjJITl9wVE56S2VtS1pWSTdVNzhReXJWSWRmdzRmUkwtNWtFREJ4ajYyMUFjaDFpNlpDaWZuZThpZ0hoRldCUGVZYWZzYjNpbzRnSVYyNDY1YVlfVHVjLUhJWXppQk1oVTVTa3VRSkE0NFl4ek55UmE2NW1qeXhVNmQ3Tl9iRkE?oc=5","date":"2025-11-12","type":"pipeline","source":"PR Newswire","summary":"Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option - PR Newswire","headline":"Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwrite","sentiment":"neutral"},{"date":"2025-11-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNMGlFYnEzSXV2RnNNazdSSVBjcWlZVEpJN21KM2dpZ2FwS0I4bVVIdGNCeHFLdWhPVFdNTGlrZ0tDdHp5MHRwdldOTzhYQzItcnAyV2kwYzJMUFdHQW5hajBmYTFqOWpydjZhNmFYWWNPbkota20xbllNLW5td1lNdDNJSWx0bmp2LXFxTllZSDN2Tm9SR0JNU0JKWXMyNUYwUC1nY2otR1RZcVFOXy1ZM2J2NmZIbTlUUC1YdQ?oc=5","date":"2025-08-18","type":"deal","source":"Pharmaceutical Technology","summary":"Boehringer Ingelheim marks retinal disease push with $327m licensing deal - Pharmaceutical Technology","headline":"Boehringer Ingelheim marks retinal disease push with $327m licensing deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxON3M2UUtPYkFUMXN6eFJDY3NRSkIyVThSa2tHdGV6Rk9QNm15UjFYdERYRGItX0JYZndrWkl1OEJYdG1UN1VFa0N3OWRFU1ZWTE81MG92Qnh3M0hlV2Jma0FYSjhxNnFUN3VWeTk5SGlVc2hTejI1ell0OTV2bk1uQ1NsWEhCbVliY0NpQkc4a29mblRHcmRBVW1lempDXy04NGxPeWh2am5rS2RNTU9nOS0wZE8?oc=5","date":"2025-08-18","type":"pipeline","source":"Fierce Biotech","summary":"Boehringer pens $327M pact with Palatin to develop new therapies for diabetic retinopathy - Fierce Biotech","headline":"Boehringer pens $327M pact with Palatin to develop new therapies for diabetic retinopathy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxPNENwZFNOUy00TGpWSmJHbWV1V2UwQU5QWjAyd2owSUdlcWV2aThqZDktLXdJLVJubmVIMFQtal8zRlgxTEY2T1U0eWFYU2d3enMwMXdYaHN4NjZKSGxOTTRTdzRXX2tFVzZOSlFLYW5ZOTE2Y1FIcXB5dFhFd2ZfdS1jdDRXVUpvTG1mUjZrYk9tcFIzbGl3YWVWZV90T3EwZ1pSeEVRdWhVT0dOb1JMZnMzMGJ1VVhWeUVxdG1hRGVia04zNnZGVTRKQUUxU3FRN0dFRGtHejlKRnJmMEx4R2x5Xzc1QVAyNS16R1A3WkFxR1VvZHdyUTREWnJYa2h2cUJlUVVmN29XMFVxZWk0MEtUdTlSWGs3Y0VNdnNCMXNCOUlieDZyTHgtX2FpYnJBN1E?oc=5","date":"2025-07-14","type":"pipeline","source":"PR Newswire","summary":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight - PR Newswire","headline":"MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNT3pRcnJIRVNFb0VSMVdQNXIwWG11RnBqSzNHa1hxdzNUellYbDJ4dDREOVU3TU02Q0lpbzFUcXIyY2lGa242YzFjZWpxSU45WS13dUduTGNFOXlQZXh5aUVGLUVCTVVLVXNhRkR1X0RDR29qc01SM1FSRmowWVQtT3pNTGVJNlhkTG5nUkdMZUdyeThZbGx5ZEdBUGNQZ1ZKQTRFTFBuNjFEU0ZLek5TNDVaNHlQNVZyY0c0SjlR?oc=5","date":"2025-05-08","type":"pipeline","source":"PR Newswire","summary":"Palatin Technologies Announces Closing of Reduced Public Offering - PR Newswire","headline":"Palatin Technologies Announces Closing of Reduced Public Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxNSjJaMU53Mmo0SXRqZWlWOHY5Tmdjek5qWnR5NnYyam5mYlJYSlJmdnhkRzEyNWRub21vTks2Q004OVRTY0s0Ri1sYzhXV0ptTW90UVVYRXhHS1EteDlSb0g1Y3dkeHVpcXU2bzJOSVc3VTZlYVI1bkwzQWlvU2ZybUFDOEctUmVzMklxRkZUQ0cwMjNETnFKOU1CZlZZbkZaQTJELTJUTW9KbkV5YW5YOHNoUXNuZzB1VUZDNUE0UERBQnVjYjd0V0J5cFBUZUllY3E3aWw0VkROR2dSbUd4ZGZBU0trSFdnczVXaWFVVzdrY1hQWVFPeWJSd0FydlN6eGx5TDd0NEhTb3d1VmF6Tk44cw?oc=5","date":"2025-05-08","type":"trial","source":"PR Newswire","summary":"Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - PR Newswire","headline":"Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNc3YwRHBMSUEwYng4eHJ0aTRHcU94NW5VLWtCaHhrcWE2VXFfNE1MaDRHZUlxb2NzeGRNZE9SOFdKLU5obVZzOFlWczhOdl8tVDlPeVI4b3BhRjlMdTc4a2g3MXNkTUx2cE0wYVhuVGF0a3hoMXlfNG90WVZuTnFmY09RZVg4TTZoU0ktbWwzdDU2T0xNV09ldkRYZlpKOXg5ZVhWX3RyeDAzOGplMzBKbEJTRExma24yOF9tbHlDRQ?oc=5","date":"2025-05-07","type":"pipeline","source":"Stock Titan","summary":"Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Stock Titan","headline":"Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxObUNuQjRGckZFa0pQcDdBcHd0dW9XSlFQMm9FUEp1SzhkTF9VMEExMWpFcldjY0pKaEV5ME5wUFVsbTRORDhzS0tXVXEtbktRUUFjSlBNQi1MVWc3dkZqOUhxcjQ0WGJ6a3R2VW4yYlJ5VXB6RDhrTTRSSjZKYXBLVnNrX2FtTFk5TVdrYzhQeHVJMVhXZW5Pcms5czRFRFZsVjBPaTVPNERtemRsdnBPMDFuZU1xWXJFNjVkcjJCbDlFSDFGNnFNSGJPWGdiSUxjaGExOTJQSmVqOFBfNmhKMl9ONEFVRWc?oc=5","date":"2024-01-03","type":"deal","source":"Business Wire","summary":"Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc. - Business Wire","headline":"Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxONzBUZzR5cE04TVdkb1h1S3p4UWFfS1pJMm5EN0Mtam1hLWI5aS1aS3lPZ0xaeXo1c2Nob0pJZ3lJa2hqTVlmYXJ4dWlYd0VBWlBadTM0V2tnWVRaUHFsSTRtbnB1djc3SzA1UFM4dUllcDE2Q1lYb2tXT1gwUkNsb1pVT1NiYWtYb01XdjE4NXRXMFJ0QkhodGZB?oc=5","date":"2023-12-20","type":"regulatory","source":"Fierce Pharma","summary":"Palatin sells female libido drug Vyleesi to Cosette for $12M, plus more in potential milestones - Fierce Pharma","headline":"Palatin sells female libido drug Vyleesi to Cosette for $12M, plus more in potential milestones","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOU0doZ2RrOFlmVDd2T0xPWkZkd2IwVTNwT1FPQVNvU1BCTnJOSE9UWS1pemVSRERLRHJ2TEJFMElPSnc2cnFtR0VWcjFURkhBLXYwc0o5U0ZlaGhrREU0Y0J1R19HSENwb2ZWbHB6RGxJeGlHOXJlb0lUSENjbzdDLTJ3N1hGelFvd1BiajFVVG1ySlI1aTlvY3BJV2RRX1RFSzRlLW91aVpBTk1NRU5OUmRqVTN0MzVieHFwWE1veTliNkdCTHFpOUdVamNNOTdibGtwdw?oc=5","date":"2023-12-20","type":"pipeline","source":"PR Newswire","summary":"Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million - PR Newswire","headline":"Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-06-30","revenueHistory":[{"value":0,"period":"2025-06-30"},{"value":4490090,"period":"2024-06-30"},{"value":4490090,"period":"2024-06-30"},{"value":4853678,"period":"2023-06-30"},{"value":4853678,"period":"2023-06-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":14898494,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-17307349,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":3266954,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}